- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Moffitt Cancer Center | Strategic Alliance Partners
Moffitt is dedicated to one lifesaving mission: to contribute to the prevention and cure of cancer. The Tampa-based facility is one of only 53 National Cancer Institute-designated Comprehensive Cancer Centers, a distinction that recognizes Moffitt’s scientific excellence, multidisciplinary research, and robust training and education. Moffitt’s expert nursing staff is recognized by the American Nurses Credentialing Center with Magnet® status, its highest distinction. With more than 7,800 team members, Moffitt has an economic impact in the state of $2.4 billion. For more information, call 1-888-MOFFITT (1-888-663-3488), visit MOFFITT.org, and follow the momentum on Facebook, Twitter, Instagram and YouTube.
Latest from Moffitt Cancer Center
Treatment Sequencing for Refractory mCRC and SUNLIGHT Study Analysis
March 28, 2024
Video
Data presented at ESMO 2023 and ASCO GI 2024 highlight the impact of prior therapy, including VEGF inhibitors or fluoropyrimidine, on mCRC treatment approach.
Considerations for Platinum-based Therapy
March 28, 2024
Video
Key factors, particularly neuropathy, drive the discussion for platinum-based therapy for patients with non-refractory mCRC.
Dr Grajales-Cruz on Future Research Directions With Teclistamab in R/R Multiple Myeloma
March 25, 2024
Video
Ariel Grajales-Cruz, MD, discusses research elucidating the role of teclistamab monotherapy for patients with relapsed/refractory multiple myeloma.
Identifying Ideal Candidates for Triplet Therapy in mCRC Treatment
March 21, 2024
Video
Considerations for patients to receive aggressive mCRC therapy regimens are navigated by the panelists.
Fatigue Associated with Bevacizumab, Fruquintinib, TAS-102 Therapies
March 21, 2024
Video
Side effect profiles driven by fruquintinib use are discussed.
Consideration for Fruquintinib Dosing and Titration
March 14, 2024
Video
Mark A Lewis, MD, and Scott Paulson, MD, share their experiences utilizing fruquintinib.
Utilizing RWE to Derive Optimal Treatment Strategy for Refractory mCRC
March 14, 2024
Video
Richard Kim, MD, discusses the significance of real-world evidence when selecting treatment sequencing strategy.
Dr Pellini on the Clinical Utility of ctDNA Assays in NSCLC
March 13, 2024
Video
Bruna Pellini, MD, discusses the utility of circulating tumor DNA assays in non–small cell lung cancer.
Dr Grajales-Cruz on the Safety of Teclistamab in Multiple Myeloma
March 13, 2024
Video
Ariel F. Grajales-Cruz, MD, discusses the real-world efficacy of teclistamab in relapsed/refractory multiple myeloma.
Dose Modifications and Tolerability Associated with mCRC Treatment Regimens
March 07, 2024
Video
Managing dose adjustments and tolerability in metastatic colorectal cancer (mCRC) treatment regimens for optimal efficacy is underscored.
FRESCO-2 Study Highlights
March 07, 2024
Video
Medical experts provide key takeaways and impacts from the FRESCO-2 study.
OncLive Peer Exchange on Allo-HSCT: Conclusion of Discussion
March 01, 2024
Video
The expert panel recaps and synthesizes key points and conclusions from each presentation and discussion over the course of the program.
Compounding Impact of TAS-102 and Bevacizumab in mCRC Treatment
February 29, 2024
Video
Marwan G Fakih, MD, drives a discussion highlighting a significant combination therapy in mCRC treatment.
Fruquintinib MoA and Toxicity Profile Overview
February 29, 2024
Video
Key safety considerations for the use of fruquintinib are explored.
Dr Baldonado on the Evolution of Targeted Therapy in NSCLC
February 28, 2024
Video
Jobelle Baldonado, MD, discusses the evolution of personalized approaches to treatment in non–small cell lung cancer.
NCCN Lists Ropeginterferon Alfa-2B As Preferred First-Line Cytoreductive Therapy for Polycythemia Vera
February 28, 2024
Article
The National Comprehensive Cancer Network recommends ropeginterferon alfa-2b as first-line cytoreductive therapy for polycythemia vera.
Dr Grajales-Cruz on Benefit With Teclistamab in Select Patients With Relapsed/Refractory Myeloma
February 27, 2024
Video
Ariel Grajales-Cruz, MD, discusses factors associated with benefit from teclistamab in heavily pretreated relapsed/refractory multiple myeloma.
The Future of Allo-HSCT and Cellular Therapies
February 23, 2024
Video
Speculation on anticipated innovations in allo-HSCT and cellular therapy technologies in the future.
Investigational Allo-HSCT for Advanced Hematologic Malignancies
February 23, 2024
Video
The expert panel shares emerging data on an engineered, allogeneic cell-based therapy administered as part of conditioning for allo-HSCT in patients with relapsed, refractory, or high-risk hematologic cancers.
Dr Kim on the Addition of NALIRIFOX to the Pancreatic Cancer Treatment Paradigm
February 22, 2024
Video
Dae Won Kim, MD, discusses findings from the NAPOLI 3 trial that support the use of NALIRIFOX in patients with metastatic pancreatic cancer.